AAPL299.11+2.10 (+0.71%) ▲|ABBV234.85+4.84 (+2.10%) ▲|ABT90.75+2.92 (+3.32%) ▲|ACN126.82+1.99 (+1.59%) ▲|ADBE199.47+4.57 (+2.34%) ▲|AMAT586.25-53.93 (-8.42%) ▼|AMD520.90-30.73 (-5.57%) ▼|AMGN347.78+3.06 (+0.89%) ▲|AMT178.42+1.99 (+1.13%) ▲|AMZN234.44+1.65 (+0.71%) ▲|AVGO383.75-8.39 (-2.14%) ▼|AXP337.06-1.01 (-0.30%) ▼|BA218.49-2.34 (-1.06%) ▼|BAC57.79+0.42 (+0.72%) ▲|BKNG169.51+1.74 (+1.04%) ▲|BLK1,020.11-31.64 (-3.01%) ▼|BMY55.68+0.98 (+1.79%) ▲|BNY147.89+1.45 (+0.99%) ▲|BRK-B493.60+4.91 (+1.00%) ▲|C145.37-0.30 (-0.21%) ▼|CAT989.58-32.71 (-3.20%) ▼|CL91.38+2.71 (+3.05%) ▲|CMCSA22.89+0.57 (+2.53%) ▲|COF198.39-2.31 (-1.15%) ▼|COP110.28+0.58 (+0.52%) ▲|COST961.01+9.66 (+1.02%) ▲|CRM154.87+4.75 (+3.16%) ▲|CSCO121.81+0.28 (+0.23%) ▲|CVS101.33+0.03 (+0.03%) ▲|CVX176.14+1.08 (+0.61%) ▲|DE598.59+0.00 (+0.00%) ▲|DHR178.54+0.35 (+0.20%) ▲|DIS103.44+0.99 (+0.96%) ▲|DUK125.06+1.54 (+1.25%) ▲|EMR144.51-5.71 (-3.80%) ▼|FDX323.30-5.48 (-1.67%) ▼|GD349.10+5.74 (+1.67%) ▲|GE357.08+1.96 (+0.55%) ▲|GEV1,048.85-78.74 (-6.98%) ▼|GILD125.78+0.91 (+0.73%) ▲|GM80.08-0.35 (-0.44%) ▼|GOOG346.84-1.95 (-0.56%) ▼|GOOGL347.35-2.21 (-0.63%) ▼|GS1,099.08-7.29 (-0.66%) ▼|HD325.50-1.13 (-0.34%) ▼|HON224.66-3.46 (-1.51%) ▼|IBM265.84+13.62 (+5.40%) ▲|INTC133.70-7.24 (-5.14%) ▼|INTU260.76+2.99 (+1.16%) ▲|ISRG401.54-1.42 (-0.35%) ▼|JNJ237.14+5.85 (+2.53%) ▲|JPM334.13+2.65 (+0.80%) ▲|KO79.93+0.40 (+0.50%) ▲|LIN517.00+0.29 (+0.06%) ▲|LLY1,104.37+2.29 (+0.21%) ▲|LMT502.25+8.65 (+1.75%) ▲|LOW214.90+0.50 (+0.23%) ▲|LRCX370.97-38.57 (-9.42%) ▼|MA488.32+4.23 (+0.87%) ▲|MCD271.75+1.65 (+0.61%) ▲|MDLZ60.66+1.15 (+1.92%) ▲|MDT80.36+1.09 (+1.38%) ▲|META564.45+0.60 (+0.11%) ▲|MMM162.40-0.82 (-0.50%) ▼|MO71.12+1.61 (+2.32%) ▲|MRK118.74+3.26 (+2.82%) ▲|MS227.48+0.39 (+0.17%) ▲|MSFT372.72+5.38 (+1.46%) ▲|MU1,072.68-138.70 (-11.45%) ▼|NEE86.58+0.50 (+0.58%) ▲|NFLX73.19+0.31 (+0.42%) ▲|NKE42.94-0.25 (-0.58%) ▼|NOW97.36+4.35 (+4.67%) ▲|NVDA201.83-6.82 (-3.27%) ▼|ORCL168.27-6.80 (-3.88%) ▼|PEP141.06+0.35 (+0.25%) ▲|PFE25.01-0.08 (-0.30%) ▼|PG150.60+2.92 (+1.98%) ▲|PLTR118.86-0.64 (-0.54%) ▼|PM177.91+4.74 (+2.74%) ▲|QCOM201.15-20.75 (-9.35%) ▼|RTX184.92+3.09 (+1.70%) ▲|SBUX100.89+0.74 (+0.74%) ▲|SCHW93.03+1.00 (+1.09%) ▲|SO94.60+1.17 (+1.25%) ▲|SPG216.71+2.14 (+1.00%) ▲|T22.87+0.77 (+3.48%) ▲|TMO466.82+2.81 (+0.61%) ▲|TMUS183.26+3.20 (+1.78%) ▲|TSLA384.06-20.99 (-5.18%) ▼|TXN302.80-29.48 (-8.87%) ▼|UBER70.55-0.88 (-1.23%) ▼|UNH407.91+1.23 (+0.30%) ▲|UNP260.49+0.58 (+0.22%) ▲|UPS106.18-1.06 (-0.99%) ▼|USB59.74+1.06 (+1.81%) ▲|V331.10+4.50 (+1.38%) ▲|VZ46.60+1.24 (+2.73%) ▲|WFC83.83-0.01 (-0.01%) ▼|WMT119.53+2.35 (+2.01%) ▲|XOM140.15+1.68 (+1.21%) ▲|AAPL299.11+2.10 (+0.71%) ▲|ABBV234.85+4.84 (+2.10%) ▲|ABT90.75+2.92 (+3.32%) ▲|ACN126.82+1.99 (+1.59%) ▲|ADBE199.47+4.57 (+2.34%) ▲|AMAT586.25-53.93 (-8.42%) ▼|AMD520.90-30.73 (-5.57%) ▼|AMGN347.78+3.06 (+0.89%) ▲|AMT178.42+1.99 (+1.13%) ▲|AMZN234.44+1.65 (+0.71%) ▲|AVGO383.75-8.39 (-2.14%) ▼|AXP337.06-1.01 (-0.30%) ▼|BA218.49-2.34 (-1.06%) ▼|BAC57.79+0.42 (+0.72%) ▲|BKNG169.51+1.74 (+1.04%) ▲|BLK1,020.11-31.64 (-3.01%) ▼|BMY55.68+0.98 (+1.79%) ▲|BNY147.89+1.45 (+0.99%) ▲|BRK-B493.60+4.91 (+1.00%) ▲|C145.37-0.30 (-0.21%) ▼|CAT989.58-32.71 (-3.20%) ▼|CL91.38+2.71 (+3.05%) ▲|CMCSA22.89+0.57 (+2.53%) ▲|COF198.39-2.31 (-1.15%) ▼|COP110.28+0.58 (+0.52%) ▲|COST961.01+9.66 (+1.02%) ▲|CRM154.87+4.75 (+3.16%) ▲|CSCO121.81+0.28 (+0.23%) ▲|CVS101.33+0.03 (+0.03%) ▲|CVX176.14+1.08 (+0.61%) ▲|DE598.59+0.00 (+0.00%) ▲|DHR178.54+0.35 (+0.20%) ▲|DIS103.44+0.99 (+0.96%) ▲|DUK125.06+1.54 (+1.25%) ▲|EMR144.51-5.71 (-3.80%) ▼|FDX323.30-5.48 (-1.67%) ▼|GD349.10+5.74 (+1.67%) ▲|GE357.08+1.96 (+0.55%) ▲|GEV1,048.85-78.74 (-6.98%) ▼|GILD125.78+0.91 (+0.73%) ▲|GM80.08-0.35 (-0.44%) ▼|GOOG346.84-1.95 (-0.56%) ▼|GOOGL347.35-2.21 (-0.63%) ▼|GS1,099.08-7.29 (-0.66%) ▼|HD325.50-1.13 (-0.34%) ▼|HON224.66-3.46 (-1.51%) ▼|IBM265.84+13.62 (+5.40%) ▲|INTC133.70-7.24 (-5.14%) ▼|INTU260.76+2.99 (+1.16%) ▲|ISRG401.54-1.42 (-0.35%) ▼|JNJ237.14+5.85 (+2.53%) ▲|JPM334.13+2.65 (+0.80%) ▲|KO79.93+0.40 (+0.50%) ▲|LIN517.00+0.29 (+0.06%) ▲|LLY1,104.37+2.29 (+0.21%) ▲|LMT502.25+8.65 (+1.75%) ▲|LOW214.90+0.50 (+0.23%) ▲|LRCX370.97-38.57 (-9.42%) ▼|MA488.32+4.23 (+0.87%) ▲|MCD271.75+1.65 (+0.61%) ▲|MDLZ60.66+1.15 (+1.92%) ▲|MDT80.36+1.09 (+1.38%) ▲|META564.45+0.60 (+0.11%) ▲|MMM162.40-0.82 (-0.50%) ▼|MO71.12+1.61 (+2.32%) ▲|MRK118.74+3.26 (+2.82%) ▲|MS227.48+0.39 (+0.17%) ▲|MSFT372.72+5.38 (+1.46%) ▲|MU1,072.68-138.70 (-11.45%) ▼|NEE86.58+0.50 (+0.58%) ▲|NFLX73.19+0.31 (+0.42%) ▲|NKE42.94-0.25 (-0.58%) ▼|NOW97.36+4.35 (+4.67%) ▲|NVDA201.83-6.82 (-3.27%) ▼|ORCL168.27-6.80 (-3.88%) ▼|PEP141.06+0.35 (+0.25%) ▲|PFE25.01-0.08 (-0.30%) ▼|PG150.60+2.92 (+1.98%) ▲|PLTR118.86-0.64 (-0.54%) ▼|PM177.91+4.74 (+2.74%) ▲|QCOM201.15-20.75 (-9.35%) ▼|RTX184.92+3.09 (+1.70%) ▲|SBUX100.89+0.74 (+0.74%) ▲|SCHW93.03+1.00 (+1.09%) ▲|SO94.60+1.17 (+1.25%) ▲|SPG216.71+2.14 (+1.00%) ▲|T22.87+0.77 (+3.48%) ▲|TMO466.82+2.81 (+0.61%) ▲|TMUS183.26+3.20 (+1.78%) ▲|TSLA384.06-20.99 (-5.18%) ▼|TXN302.80-29.48 (-8.87%) ▼|UBER70.55-0.88 (-1.23%) ▼|UNH407.91+1.23 (+0.30%) ▲|UNP260.49+0.58 (+0.22%) ▲|UPS106.18-1.06 (-0.99%) ▼|USB59.74+1.06 (+1.81%) ▲|V331.10+4.50 (+1.38%) ▲|VZ46.60+1.24 (+2.73%) ▲|WFC83.83-0.01 (-0.01%) ▼|WMT119.53+2.35 (+2.01%) ▲|XOM140.15+1.68 (+1.21%) ▲|
20.6 C
New York
Tuesday, June 23, 2026

Tag: cancer

newssourceFORcompanyinformationcontent1marketreleases

PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO

SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (“the Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that Larry L. Wood will join the Company as president and CEO effective September 2, 2025. Dr. Reza Zadno will retire as president, CEO, and director effective September 1, 2025.

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025.

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK, July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO)...

Knee Replacement Surgery Market worth $16.17 billion in 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The global Knee Replacement Surgery Market, valued at US$10.86 billion in 2023 stood at US$12.00 billion in 2025...

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohortsDarovasertib has received U.S. FDA Breakthrough Therapy Designation...

START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials

START enhances its global leadership by integrating Advarra's advanced regulatory and technology solutions, creating a seamlessly connected site network to accelerate trials and relieve...

NANO Nuclear Joins the Canadian Nuclear Association to Support the Adoption of Next-Generation Advanced Nuclear Energy Technologies in Canada

New York, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that it has joined the Canadian Nuclear Association (CNA), the leading Canadian nuclear industry advocacy group since 1960.

LUNGevity Foundation Joins 2025 LungXperience Tour to Promote Lung Health and Early Detection Across the U.S.

Organization to Participate in 12 National Events as Part of Innovative Health Education Initiative WASHINGTON, July 24, 2025 /PRNewswire/ -- LUNGevity Foundation, the nation's leading...

Flow Cytometry Market Research Report 2025-2029 | Technology Convergence and Cell-Based Analytics Fuel Growth in the Life Sciences Market

Flow Cytometry's growth accelerates as immuno-oncology and liquid biopsy markets expand, driving cancer research investment. Explore advancements in single-cell genomics and biotech opportunities in our comprehensive report. Stay ahead with insights on market trends, technology, and growth potential. 
Flow Cytometry's growth accelerates as immuno-oncology and liquid biopsy markets expand, driving cancer research investment. Explore advancements in single-cell genomics and biotech opportunities in our comprehensive report. Stay ahead with insights on market trends, technology, and growth potential.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCancer

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers